|Bid||68.62 x 0|
|Ask||68.64 x 0|
|Day's Range||67.30 - 68.72|
|52 Week Range||60.17 - 79.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FRANKFURT (Reuters) - German healthcare group Fresenius (FREG.DE) will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief ...
German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying. Last year Fresenius ...
U.S. regulators warned Fresenius SE last month that workers in one of its cancer-drug plants ignored tests that found the products made there weren’t meeting sterility standards.
U.S. regulators warned Fresenius SE after the company’s Indian plant that makes cancer-drug ingredients for the U.S. market aborted hundreds of drug-quality tests because they seemed like they were going ...
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday. "While we've been focused on a 2017 close, it's now clear that closing in early 2018 is more likely, and we're quite comfortable with this timeline," the spokesman said.
German healthcare group Fresenius SE (FREG.DE) said the planned takeover of Akorn (AKRX.O), a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected. Akorn's business has deteriorated since Fresenius struck the acquisition agreement in April, valuing the maker of medical creams, ophthalmic drugs and oral liquids at $4.75 billion (3.6 billion pounds). Akorn's operating income has slumped on supply disruptions and competition for a range of drugs.
Strong growth in Health Care Products and Health Care Services segments drove Fresenius's (FMS) third-quarter revenues. Lackluster performance by the renal pharmaceutical segment is a concern.
German healthcare group Fresenius SE said on Thursday that weakness at Akorn , the U.S. maker of liquid generic drugs it has agreed to buy, could continue into next year but the deal was still worth it over the longer term. The 2018 targets for Akorn, which Fresenius plans to take over at the end of this year, were "challenging", the diversified drugmaker said in presentation slides posted on its website after the release of its quarterly results.
German healthcare group Fresenius said third-quarter adjusted net income gained 11 percent on higher drug sales and helped by the addition of Spanish hospitals chain Quironsalud. Quarterly net income adjusted ...
New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday, Speaking at the Sohn Conference ...
Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.
E*TRADE Financial Corporation, Big Five Sporting Goods, Micron Technology, Electrolux AB and Fresenius SE & Co. highlighted as Zacks Bull and Bear of the Day
The Bad Homburg, Germany-based company said it had profit of 48 cents per share. The dialysis services provider posted revenue of $4.92 billion in the period. Fresenius shares have increased 12 percent ...
Nestle SA Chief Executive Officer Mark Schneider previously transformed a sleepy German hospital operator into a stock-market darling via more than 30 acquisitions. Now he wants to return to dealmaking ...
For all the problems with US healthcare, there’s one service that’s been fully funded by the government since 1972. During his troubled tenure as president, Richard Nixon signed a bill into law that provided access to dialysis—a process which externally filters the blood when kidneys fail to do so—to anyone who needs it. As of…
European shares slipped slightly from the 20-month highs they hit in the previous session, as investors locked in some profits following some underwhelming company results. Shares in several Apple suppliers fell after the smartphone giant reported a surprise dip in sales of its flagship iPhone. Dialog Semiconductor shares slid 2.9 percent at the open.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.